Science Explorer Interactive view Map
Institution · Vienna · Austria

Central European Cooperative Oncology Group

cecog.orgROR OpenAlex
Research works
36
▼ 4% vs 2013–17
Citations
609
16.7 per fractional work
Top-10% rate
12.5%
record average 16.5%
Open access
54%
world 28%

Not ranked overall: Central European Cooperative Oncology Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.21× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 18.74× its world share, 1 worksImmunology and Micro…Computer Science: 0.11× its world share, 0 worksComputer ScienceEngineering: 0.12× its world share, 0 worksEngineeringMedicine: 3.23× its world share, 4 worksMedicineEconomics, Econometrics and Finance: 0.85× its world share, 0 worksEconomics, Econometr…Social Sciences: 0.63× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 18.7×. Every wedge is a field page.

Which keywords describe research at Central European Cooperative Oncology Group?

By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Targeted Therapy, Metastatic Breast Cancer, Radiotherapy, Breast Cancer, Clinical Trials, Molecular Subtypes and Immunity.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy7▲ 28×11 topics
  2. Targeted Therapy5▲ 58×4 topics
  3. Metastatic Breast Cancer4▲ 159×2 topics
  4. Breast Cancer3▲ 30×5 topics
  5. Radiotherapy3▲ 23×4 topics
  6. Clinical Trials3▲ 13×3 topics
  7. Molecular Subtypes3▲ 89×2 topics
  8. Immunity3▲ 22×3 topics
  9. Clinical Practice Guidelines3▲ 13×4 topics
  10. Quality of Life3▲ 5.5×3 topics
  11. Survival Analysis3▲ 27×4 topics
  12. Tumor Microenvironment3▲ 21×4 topics
  13. Chemotherapy-Induced Peripheral Neuropathy3▲ 142×1 topic
  14. Taxanes3▲ 142×1 topic
  15. Adjuvant Therapy2▲ 52×2 topics
  16. Cancer Immunotherapy2▲ 41×2 topics
  17. Antigen Presentation2▲ 56×1 topic
  18. Dendritic Cells2▲ 48×1 topic
  19. Gene Expression2▲ 9.1×2 topics
  20. Neoadjuvant Therapy2▲ 25×2 topics
  21. ALK Inhibitors2▲ 92×1 topic
  22. Cancer2▲ 3.7×7 topics
  23. EGFR Mutations2▲ 92×1 topic
  24. Immunotherapy2▲ 8.0×7 topics
  25. Prognostic Factors2▲ 11×6 topics
  26. Breast Tumours2▲ 94×1 topic
  27. HER22▲ 157×1 topic
  28. Trastuzumab2▲ 111×1 topic
  29. Treatment Response2▲ 94×1 topic
  30. Immune Checkpoint Blockade2▲ 78×1 topic
  31. PD-1 and PD-L12▲ 78×1 topic
  32. Precision Medicine2▲ 13×2 topics
  33. CT Screening1▲ 67×1 topic
  34. Cancer Genomics1▲ 69×1 topic
  35. Lung Cancer1▲ 23×1 topic
  36. Mutational Signatures1▲ 69×1 topic
  37. Tumor Staging1▲ 43×2 topics
  38. CDK4/6 Inhibitors1▲ 214×1 topic
  39. Cetuximab1▲ 39×1 topic
  40. Palbociclib1▲ 214×1 topic

Which research topics does Central European Cooperative Oncology Group publish most on?

By volume in 2022–2025: Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research and Lung Cancer Research Studies.

Immunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksMonoclonal and Polyclona…1Monoclonal and Polyclonal Antibodies Research: 1 fractional worksLung Cancer Research Stu…0Lung Cancer Research Studies: 0 fractional worksEthics and Social Impacts of AI: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksLung Cancer Diagnosis an…0Lung Cancer Diagnosis and Treatment: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional worksImmune responses and vaccinations: 0 fractional works
ImmunologyOncologyRadiology, Nuclear Medicine and ImagingSafety Research3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Immunotherapy and Immune Responses Immunology 1 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  4. 4 Lung Cancer Research Studies Oncology 0 works
  5. 5 Ethics and Social Impacts of AI Safety Research 0 works
  6. 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  7. 7 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  8. 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  9. 9 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
  10. 10 Immune responses and vaccinations Immunology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available54.2%not open45.8%

World: 28% of research is openly available.

with international co-authors33.8%domestic only66.2%

World: 19% is written across borders.

How has Central European Cooperative Oncology Group's research output changed?

Output in 2018–2022 was 4% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Vienna

All research institutions in Vienna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.